Rivaroxaban Alternatives in Montana
Compare generic and therapeutic alternatives to Rivaroxaban (rivaroxaban) available at Montana pharmacies. Save up to 75% on your prescription — no insurance required.
Top Alternatives in Montana
Apixaban (generic Eliquis)
therapeutic
Twice-daily DOAC — similar efficacy, possibly lower bleeding risk
Avg cash price: $130/mo
Warfarin
therapeutic
Older anticoagulant requiring INR monitoring — much cheaper
Avg cash price: $10/mo
Xarelto (brand rivaroxaban)
brand
Brand name — same drug at nearly 4× the cost
Avg cash price: $540/mo
Montana Prescription Assistance Programs
Montana Medicaid Rx
Prescription drug coverage for Montana Medicaid beneficiaries through the state's managed care program.
Eligibility: Low-income Montana adults up to 138% FPL via the HELP (Health and Economic Livelihood Partnership) expansion program.
Frequently Asked Questions
Is there a generic for rivaroxaban (Xarelto)?
Yes — generic rivaroxaban became available in the US in 2024. It is bioequivalent to brand Xarelto and significantly cheaper, typically $120–$160/month.
What is the main advantage of rivaroxaban being once-daily?
Once-daily dosing (for most indications) improves medication adherence compared to twice-daily DOACs like apixaban. However, apixaban has a slightly larger evidence base for lower GI bleeding.
Does rivaroxaban require INR monitoring?
No — like all DOACs, rivaroxaban does not require routine blood monitoring. This is a major advantage over warfarin, which requires regular INR testing and dietary restrictions.
Is apixaban or rivaroxaban better for atrial fibrillation?
Both reduce stroke risk effectively in AF. Meta-analyses suggest apixaban may have a slightly better bleeding safety profile. Both are reasonable choices; your cardiologist decides based on your full medical picture.
Can Script Unlock help with rivaroxaban costs?
Yes. Generic rivaroxaban is available through Script Unlock pharmacies. Post your prescription to receive competitive cash-price bids from pharmacies in the network.